Some have argued, however, that, due to the variability in longitudinal changes in biomarker levels in CSF between patients, the usefulness of t-Tau, p-Tau, and α-syn in diagnosing and prognosing PD may be diminished. This evidence concerns the gene MAPT and Parkinson disease.